OptiNose up after additional chronic sinus treatment trial data

OptiNose

08/07/2022 13:33

** Shares of OptiNose Inc  OPTN.O  rise 3.8% to $4.09
premarket
    ** Co reports additional data from two late-stage studies
testing drug-device combination Xhance as a treatment for
chronic sinusitis  urn:newsml:reuters.com:*:nFWN2YP1H7
    ** Xhance demonstrated an improvement in objective measures
of disease relative to placebo, data pooled from the studies
showed - OPTN
    ** Chronic sinusitis is a condition in which cavities around
nasal passages are inflamed and swollen for at least 12 weeks,
for which there are currently no FDA-approved treatments
    ** Xhance is already approved in the U.S. for treatment of
nasal polyps, a condition which causes swelling of the nasal
lining
    ** OPTN shares had more than doubled in value YTD, as of
last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))